Remicade Infusion Management Program

Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Crohn Disease Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Immune System Diseases Inflammatory Bowel Diseases Intestinal Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Montreal, Quebec, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject is a good candidate to receive infliximab as per the Product Monograph
Subject is prescribed infliximab by an appropriate physician
Subject receives infusion in a community infusion centre.
Subject has signed the approved consent form.

Exclusion criteria

Not specified in the protocol

Treatment and study plan

Primary outcomes

Type and frequency of infusion reactions

Time frame: Up to 7 years
Pre-infusion treatments and efficacy

Time frame: Up to 7 years
Infusion reaction management approaches

Time frame: Up to 7 years
The number of subjects with adverse events

Time frame: Up to 7 years

Sponsors and collaborators

Lead sponsor

Janssen Inc.

Industry

Registry information

Acronym: RemiTRAC

Important dates

Study start: 2005
Primary completion: 2012
Study completion: 2012
First posted: Jul 29, 2008
Registry last updated: Jan 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed